:Tezacitabine

{{chembox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 394859833

| ImageFile=Tezacitabine.png

| ImageSize=200px

| IUPACName=(2′E)-2′-Deoxy-2′-(fluoromethylidene)cytidine

| SystematicName=4-Amino-1-[(2R,3E,4S,5R)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2(1H)-one

| OtherNames=

|Section1={{Chembox Identifiers

| UNII_Ref = {{fdacite|changed|FDA}}

| UNII = 7607Y95N9S

| CASNo_Ref = {{cascite|correct|??}}

| CASNo=130306-02-4

| PubChem=6435808

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = 4940503

| SMILES=OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)/C([C@@H]1O)=C/F

| InChI = 1/C10H12FN3O4/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17/h1-3,6,8-9,15-16H,4H2,(H2,12,13,17)/b5-3+/t6-,8+,9-/m1/s1

| InChIKey = GFFXZLZWLOBBLO-ASKVSEFXBD

| StdInChI_Ref = {{stdinchicite|changed|chemspider}}

| StdInChI = 1S/C10H12FN3O4/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17/h1-3,6,8-9,15-16H,4H2,(H2,12,13,17)/b5-3+/t6-,8+,9-/m1/s1

| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}

| StdInChIKey = GFFXZLZWLOBBLO-ASKVSEFXSA-N

}}

|Section2={{Chembox Properties

| C=10 | H=12 | F=1 | N=3 | O=4

| Appearance=

| Density=

| MeltingPt=

| BoilingPt=

| Solubility=

}}

|Section3={{Chembox Hazards

| MainHazards=

| FlashPt=

| AutoignitionPt =

}}

}}

Tezacitabine is a ribonucleotide reductase inhibitor. It is a synthetic purine nucleoside analogue with potential antineoplastic activity. It is used in synthetic DNA.{{cite journal |vauthors=Tsimberidou AM, Alvarado Y, Giles FJ |title=Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies |journal=Expert Rev Anticancer Ther |volume=2 |issue=4 |pages=437–48 |date=August 2002 |pmid=12647987 |doi=10.1586/14737140.2.4.437 |s2cid=30047759 |url=http://www.future-drugs.com/doi/abs/10.1586/14737140.2.4.437?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov|url-access=subscription }}